Duane Roth Endowed Award Lecture

2018 Symposium

Directions and Parking

2017 Symposium

2017 Symposium Photos

2016 Symposium

2015 Symposium

2015 Agenda and Bios

2015 Symposium Photos

2014 Symposium

2014 Agenda and Bios

2013 Featured Talks

2013 Symposium Photos

Previous Symposia

2018 Symposium Featured Talks


Please enjoy the featured talks below from our recent symposium. Thank you!

Please note: These videos are for private viewing only. Any unintended use of the videos without consent is prohibited.

Welcome Remarks


Ida Deichaite, PhD, Symposium Organizer, UC San Diego Moores Cancer Center
Pradeep Khosla, PhD, Chancellor, UC San Diego



Welcome Remarks


Thomas Kipps, MD, PhD
Symposium Chair, UC San Diego Moores Cancer Center







2018 Symposium


The 14th Moores Cancer Center Industry/Academia Translational Oncology Symposium was held on Thursday, February 22, 2018.

Duane Roth Award Lecture
Engineered T-Cells: The Sky is the Limit

Carl June, MD

Richard W. Vague Professor Of Immunotherapy
Perelman School Of Medicine
University Of Pennsylvania

Keynote Speaker
A New Model for Translational Research in the Nonprofit Sector

Peter Schultz, PhD

Chief Executive Officer
California Institute for Biomedical Research


Opening Remarks
Ida Deichaite, PhD, UC San Diego Moores Cancer Center

Mutational Signatures for Cancer Treatment and Cancer Prevention
Ludmil Alexandrov, PhD, UC San Diego Moores Cancer Center

Duane Roth Award Presenter
David Brenner, MD, Dean, UC San Diego SOM & Health Sciences

Junior Scientist Presentation: Dual PI3K/BRD4 Inhibition as a Novel Therapeutic Strategy for Hepatocellular Carcinoma
Adam Burgoyne, MD, PhD, UC San Diego Moores Cancer Center

The New Generation of Antibody Drug Conjugates: Intersection of Target and Payload
Julia Coronella, PhD, Tanabe Research Labs

Moores Cancer Center Overview
Ezra Cohen, MD, UC San Diego Moores Cancer Center

Symposium Introduction
Ida Deichaite, PhD, UC San Diego Moores Cancer Center

In silico drug discovery of dual inhibitors of combinatorial synthetic lethality inhibitors in the era of precision medical oncology; proof of concept
Donald Durden, MD, PhD, UC San Diego Moores Cancer Center

Role of neutrophil-mediated inflammation in colorectal cancer
Napoleone Ferrara, MD, UC San Diego Moores Cancer Center

A Personalized Cancer Immunotherapy Paradigm: Simple solutions to address complex options for patients
Priti Hedge, PhD, Genentech

The Next Wave: BCMA Targeted CAR-T Cells for Multiple Myeloma
Kristen Hege, MD, Celgene

Welcome Remarks
Pradeep Khosla, PhD, Chancellor, UC San Diego

Moores Cancer Center Introduction
Scott Lippman, MD, UC San Diego Moores Cancer Center

Inhibition of Difficult to Drug Tumor Cell and Immuno-Oncology targets with Next Generation Antisense Inhibitors
Robert MacLeod, PhD, Ionis Pharmaceuticals

Systematic Mapping of Genetic Vulnerabilities in Cancer via Novel CRISPR-Cas9 Screening Methodologies
Prashant Mali, PhD, UC San Diego Moores Cancer Center

Patient Advocacy Presentation
Brian McCloskey, Patient Advocate

Targeting PARP in Prostate Cancer: Promise and Pitfalls
Rana McKay, MD, UC San Diego Moores Cancer Center

Patient Advocacy Presentation
Bryce Olson, Patient Advocate

Gene Control Approach to Manipulate Cell State: Sensitizing Cancer Cells to Antibody-mediated Attack
Dave Orlando, PhD, Syros Pharmaceuticals

Killing Cancer Stem Cells in Brain Cancer
Jeremy Rich, MD, UC San Diego Moores Cancer Center


For our out of town attendees: We recommend staying at the Estancia La Jolla Hotel and Spa for your lodging needs. The UCSD corporate rate is subject to availability and this rate is $195 when it is available. It is currently available for Wednesday, Feb. 21st, and rooms can be booked via this link. We encourage you to make your reservations as soon as possible due to availability.




ABOUT THIS SYMPOSIUM

Contemporary leaders of oncology are driven to redefine the notion of curative medicine by skillfully leveraging the power of collaboration to optimize everyone’s unique expertise and stretch research dollars in order to drive innovation. They are also changing clinical trial paradigms and emphasizing combination immunotherapy, new therapeutic modalities, and precision diagnosis. Already, as a result of these efforts, the oncology community can treat cancer patients and combat cancer at the molecular level.

The annual Industry/Academia Translational Oncology Symposium at Moores Cancer Center, now celebrating its 14th year, was created to support multi-modality collaborations and foster new partnerships in order to speed new therapies to patients. Each year the Symposium’s esteemed presenters from around the world, including clinicians, researchers, and top decision makers from industry and academia, attest to just how necessary it was for them to surmount multiple obstacles, in and out of the lab, in order to achieve success and help patients. The forum provides a platform for oncology innovators to highlight their interdisciplinary approach, as opposed to discussion on a specific type of cancer. Case study presentations showcase successful efforts, the challenges that they encountered, and the lessons they have learned from the process.

SYMPOSIUM FORMAT

To address the need for dialogue amongst all leaders of cancer research, the Symposium promotes interaction and discussion throughout the entire program. Invited speakers give presentations that range in length, and include a keynote presentation, numerous presenters from faculty and industry, young investigator presentation, interactive discussion panels, and poster sessions, highlighting rapidly emerging cancer science. Discussions continue throughout breaks and lunch, and culminate in a networking reception. Additionally, a dinner consisting of Symposium speakers and sponsors held prior to the event creates an opportunity for introductions to be made and work to be discussed in a relaxed, collegial setting. Through the Symposium’s emphasis on translational oncology and drug development, we shepherd researchers and physicians to foster fruitful, ongoing relationships and partnerships with local, regional, and national biotechnology and pharmaceutical companies, ultimately resulting in curative therapies that advance global cancer treatment paradigms.

TARGET AUDIENCE

The field of oncology is brimming with innovators and investigators ready to blaze new pathways for bringing the most effective novel therapies out of the laboratory to the patients. Clinicians, researchers, and top decision makers are critical in the process of translation to deliver curative cancer therapies. Our goal is to unite these individuals and provide a forum through which they can network and collaborate, while celebrating the community’s successful efforts.

TOPICS WILL INCLUDE

  • Immunotherapy
  • Precision medicine
  • New therapeutic approaches in numerous cancers
  • Orphan drug oncology indications
  • Innovative clinical trial modalities
  • Funding innovation


ABOUT THE LOCATION

San Diego provides an ideal environment for successful partnerships and collaborations: The intersection of academia, biomedical research, top-notch health care providers, and entrepreneurship allow innovation to abound. San Diego’s position as a global hub for biomedical innovation serves as a role model for translational oncology on a national level.




Symposium Organizers and Chairs


Symposium Organizers:

Scott Lippman, MD
Director
UC San Diego Moores Cancer Center


Ida Deichaite, PhD
Director, Industry Relations
UC San Diego Moores Cancer Center


Symposium Co-Chairs:

Rafael Bejar, MD, PhD
Assistant Professor of Medicine
UC San Diego Moores Cancer Center


Tom Kipps, MD, PhD
Professor of Medicine, Evelyn and Edwin Tasch Chair in Cancer Research
Deputy Director of Research Operations
UC San Diego Moores Cancer Center










We Thank Our Supporters: